
Dexcom (DXCM) Stock
Diabetes monitoring leader selling continuous glucose monitoring systems. Here's the price, business snapshot, and what's worth knowing about Dexcom in November 2026.
DexCom, Inc. (DXCM) designs and sells continuous glucose monitoring (CGM) systems used by people with diabetes and healthcare providers. Its product suite—sensors, transmitters and supporting software—aims to provide real‑time glucose readings and trend data, with recurring revenue from consumable sensors and subscription services. Key positives include strong adoption in type 1 diabetes, a growing addressable market among type 2 patients, ongoing product upgrades (including smaller form factors) and partnerships with insulin‑delivery firms. Risks include competitive pressure (from established medical device makers and newer entrants), reimbursement and regulatory outcomes across markets, supply chain constraints and the potential for device recalls or pricing pressure. With a market capitalisation around $27.4bn, DexCom is often viewed as a growth‑oriented medical device company; investors should weigh revenue visibility from consumables against execution and regulatory risks. This is general information only, not personalised investment advice; returns are not guaranteed and share values can fall as well as rise.
Why It’s Moving

Dexcom Targets Record Patient Growth and Expands European Manufacturing Footprint
- Executives highlighted expectations for a record number of new patients in 2026, citing preparation for a potential expansion of Medicare coverage for continuous glucose monitoring.
- The company officially opened a state-of-the-art manufacturing facility in Athenry, Ireland, marking a major milestone in its investment in Europe, the Middle East, and Africa.
- Management discussed these growth drivers and strategic updates during a recent investor conference, signaling confidence in both market adoption and operational capacity.

Dexcom Targets Record Patient Growth and Expands European Manufacturing Footprint
- Executives highlighted expectations for a record number of new patients in 2026, citing preparation for a potential expansion of Medicare coverage for continuous glucose monitoring.
- The company officially opened a state-of-the-art manufacturing facility in Athenry, Ireland, marking a major milestone in its investment in Europe, the Middle East, and Africa.
- Management discussed these growth drivers and strategic updates during a recent investor conference, signaling confidence in both market adoption and operational capacity.
Six-Month Growth Performance
When is the next earnings date for DEXCOM INC (DXCM)?
No confirmed upcoming earnings date has been announced for DXCM as of November 16, 2026. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous quarter's close, the next report is expected in February 2027. This anticipated release will cover financial results for the fourth quarter and full year of fiscal 2026. Investors should monitor official corporate communications for the precise scheduling of this event.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying DEXCOM's stock, believing its value could rise significantly.
Financial Health
Dexcom is performing well with strong revenue and profits, while maintaining healthy cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue growth
Consumable sensors and subscription services support revenue predictability, though sales can fluctuate with reimbursement and competitive dynamics.
Product innovation pipeline
Smaller sensors, improved accuracy and system integrations keep the product roadmap active, but technical or regulatory setbacks can affect adoption.
Global expansion potential
International markets present sizeable opportunity as CGM adoption rises, balanced by differing regulatory regimes and payer systems that can slow rollout.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.